AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21429226 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-professional mentor support (weekly home visiting for 12 months)
Number of subjects: 215
Study 19646193 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape seed extract (600 mg/day)
Number of subjects: 32
Study 19646193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 19280386 — intervention group
Group type: EXPERIMENTAL
Intervention: Employed women (hired group)
Number of subjects: 736
Study 19280386 — intervention group
Group type: COMPARATOR
Intervention: Not hired women (control group)
Number of subjects: 736
Study 15473613 — intervention group
Group type: EXPERIMENTAL
Intervention: Method A: Seldinger guide-wire in the distal lumen
Number of subjects: 100
Study 15473613 — intervention group
Group type: EXPERIMENTAL
Intervention: Method B: Middle lumen filled with saline 10% fluid column
Number of subjects: 100
Study 15473613 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography after surgery
Number of subjects: 100
Study 11887655 — intervention group
Group type: EXPERIMENTAL
Intervention: Steri‐Oss implant system
Number of subjects: 24
Study 11887655 — intervention group
Group type: EXPERIMENTAL
Intervention: Southern Implants system
Number of subjects: 24
Study 9773737 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg t.i.d.)
Number of subjects: 1418
Study 9773737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1418
Study 7530821 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxy‐ or xylometazoline nasal spray for 30 days
Number of subjects: 13
Study 3294616 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg piretanide once or twice daily
Number of subjects: 0
Study 3294616 — intervention group
Group type: COMPARATOR
Intervention: 50 mg hydrochlorothiazide plus 5 mg amiloride once daily
Number of subjects: 0
Study 29157328 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer acceptance
Number of subjects: 273
Study 29157328 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer rejection
Number of subjects: 273
Study 29157328 — intervention group
Group type: COMPARATOR
Intervention: Exposure to peers (neutral condition)
Number of subjects: 273
Study 28716617 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity Therapy (DT)
Number of subjects: 56
Study 28716617 — intervention group
Group type: EXPERIMENTAL
Intervention: Waitlist Dignity Therapy (WDT)
Number of subjects: 56
Study 28716617 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Review (LR)
Number of subjects: 56
Study 28716617 — intervention group
Group type: COMPARATOR
Intervention: Dignity Therapy (DT) and Waitlist Dignity Therapy (WDT)
Number of subjects: 56
Study 25801893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive regimen (IR) of cholecalcipherol (300,000 UI initial bolus followed by 50,000 UI monthly)
Number of subjects: 34
Study 25801893 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (SR) of cholecalcipherol (25,000 UI monthly)
Number of subjects: 34
Study 25801893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (IR and SR)
Number of subjects: 34
Study 24061864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin administered at 6:00
Number of subjects: 0
Study 24061864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin administered at 18:00
Number of subjects: 0
Study 21568083 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone 2.5 mg/day
Number of subjects: 56
Study 21568083 — intervention group
Group type: EXPERIMENTAL
Intervention: CCHT 2 mg estradiol plus 1 mg norethisteron acetate
Number of subjects: 56
Study 21568083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 19491916 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplement (500 mg L-carnitine per day as L-carnitine L-tartrate) (n=13)
Number of subjects: 26
Study 19491916 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=13)
Number of subjects: 26
Study 19491916 — intervention group
Group type: COMPARATOR
Intervention: Control group (Placebo)
Number of subjects: 26
Study 16955313 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS
Number of subjects: 27
Study 16955313 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Hz rTMS
Number of subjects: 27
Study 16955313 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 27
Study 15144493 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong African American Families Program (SAAF)
Number of subjects: 0
Study 15144493 — intervention group
Group type: COMPARATOR
Intervention: Control families
Number of subjects: 0
Study 10662566 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine (PVP-I) in scrub formulation followed by alcoholic PVP-I
Number of subjects: 44
Study 10662566 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine in scrub formulation followed by alcoholic chlorhexidine
Number of subjects: 44
Study 9305480 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (1 mg b.d.) + Omeprazole (20 mg b.d.)
Number of subjects: 60
Study 9305480 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (1 mg b.d.) + Lansoprazole (30 mg b.d.)
Number of subjects: 60
Study 9305480 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (1 mg b.d.) + Ranitidine (300 mg b.d.)
Number of subjects: 60
Study 9305480 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 50 years
Number of subjects: 60
Study 9305480 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-eradicated patients
Number of subjects: 60
Study 1410163 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine 20 mg
Number of subjects: 100
Study 1410163 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine 5 mg
Number of subjects: 100
Study 1410163 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine 10 mg
Number of subjects: 100
Study 1410163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1410163 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine (all doses)
Number of subjects: 100
Study 3931138 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral physostigmine at 2 mg every 2 hours
Number of subjects: 8
Study 3931138 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral physostigmine at lower doses
Number of subjects: 8
Study 3931138 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 8
Study 31882732 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 60
Study 31882732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29999597 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic saline irrigation plus oxymetazoline hydrochloride 0.05% nasal spray (saline+oxymetazoline group)
Number of subjects: 0
Study 29999597 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline irrigation (saline group)
Number of subjects: 0
Study 26937924 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of DEX in Ringer solution at a rate of 0.25 μg/kg/h
Number of subjects: 75
Study 26937924 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous infusion of saline in Ringer solution
Number of subjects: 75
Study 24517384 — intervention group
Group type: EXPERIMENTAL
Intervention: My Road Ahead intervention alone
Number of subjects: 150
Study 24517384 — intervention group
Group type: EXPERIMENTAL
Intervention: My Road Ahead intervention plus a moderated online forum
Number of subjects: 150
Study 24517384 — intervention group
Group type: COMPARATOR
Intervention: Moderated online forum alone
Number of subjects: 150
Study 22943135 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard branded packages
Number of subjects: 640
Study 22943135 — intervention group
Group type: COMPARATOR
Intervention: Plain packaging (without brand imagery)
Number of subjects: 640
Study 22943135 — intervention group
Group type: COMPARATOR
Intervention: Plain packaging without descriptors
Number of subjects: 640
Study 22943135 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded packs
Number of subjects: 640
Study 19959930 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Review intervention (4 individual sessions, structured along 14 questions)
Number of subjects: 22
Study 17222105 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantial recovery at day 1 (defined as 75% improvement in NIHSS)
Number of subjects: 0
Study 17222105 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantial recovery at day 7 (defined as 65% improvement in NIHSS)
Number of subjects: 0
Study 17222105 — intervention group
Group type: EXPERIMENTAL
Intervention: Other thresholds for recovery at day 1 (>50%, 80%, 90%, 100%)
Number of subjects: 0
Study 17222105 — intervention group
Group type: EXPERIMENTAL
Intervention: Other thresholds for recovery at day 7 (>50%, 60%, 70%, 90%, 100%)
Number of subjects: 0
Study 14999611 — intervention group
Group type: EXPERIMENTAL
Intervention: T-1249 monotherapy (subcutaneous injection) at doses ranging from 6.25 to 192 mg/day for 14 days
Number of subjects: 115
Study 12219065 — intervention group
Group type: EXPERIMENTAL
Intervention: LSE plus moderate-intensity PT
Number of subjects: 74
Study 12219065 — intervention group
Group type: EXPERIMENTAL
Intervention: LSE plus high-intensity PT
Number of subjects: 74
Study 12219065 — intervention group
Group type: COMPARATOR
Intervention: LSE
Number of subjects: 74
Study 9839758 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 4.0 mg
Number of subjects: 48
Study 9839758 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 6.0 mg
Number of subjects: 48
Study 9839758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8080942 — intervention group
Group type: EXPERIMENTAL
Intervention: Pest control operators
Number of subjects: 359
Study 8080942 — intervention group
Group type: COMPARATOR
Intervention: Licensed for 10-19 years
Number of subjects: 359
Study 8080942 — intervention group
Group type: COMPARATOR
Intervention: Licensed for 20 or more years
Number of subjects: 359
Study 8080942 — intervention group
Group type: COMPARATOR
Intervention: Lagged years of licensure
Number of subjects: 359
Study 8080942 — intervention group
Group type: COMPARATOR
Intervention: Non-pest control workers
Number of subjects: 359
Study 2589098 — intervention group
Group type: EXPERIMENTAL
Intervention: Validity of the location cue
Number of subjects: 0
Study 2589098 — intervention group
Group type: EXPERIMENTAL
Intervention: Validity of the form cue
Number of subjects: 0
Study 2589098 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 0
Study 802925 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 27
Study 802925 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 27
Study 31303297 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider group (report cards shared with health providers)
Number of subjects: 3133
Study 31303297 — intervention group
Group type: EXPERIMENTAL
Intervention: Community group (report cards shared with community members)
Number of subjects: 3133
Study 31303297 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider and community group (report cards shared with both health providers and community members)
Number of subjects: 3133
Study 31303297 — intervention group
Group type: COMPARATOR
Intervention: Control group (report cards not shared)
Number of subjects: 3133
Study 28235492 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (Group P, n=14)
Number of subjects: 30
Study 28235492 — intervention group
Group type: COMPARATOR
Intervention: Morphine (Group M, n=16)
Number of subjects: 30
Study 28235492 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (Group P)
Number of subjects: 30
Study 28235492 — intervention group
Group type: COMPARATOR
Intervention: Morphine (Group M)
Number of subjects: 30
Study 28235492 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 25733651 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss (WL) through caloric restriction
Number of subjects: 38
Study 25733651 — intervention group
Group type: COMPARATOR
Intervention: Weight Maintenance (WM)
Number of subjects: 38
Study 25733651 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss (WL)
Number of subjects: 38
Study 25733651 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss (WL) and Weight Maintenance (WM)
Number of subjects: 38
Study 23985261 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus thalidomide
Number of subjects: 61
Study 23985261 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 61
Study 21625083 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of hemodialysis at an estimated glomerular filtration rate (eGFR) of 10‐14 ml/min
Number of subjects: 362
Study 21625083 — intervention group
Group type: COMPARATOR
Intervention: Late initiation of hemodialysis at an estimated glomerular filtration rate (eGFR) of 5‐7 ml/min
Number of subjects: 362
Study 21625083 — intervention group
Group type: COMPARATOR
Intervention: Late initiation of hemodialysis
Number of subjects: 362
Study 21625083 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of hemodialysis
Number of subjects: 362
Study 19365548 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50mg)
Number of subjects: 20
Study 19365548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16578980 — intervention group
Group type: EXPERIMENTAL
Intervention: DEET
Number of subjects: 10
Study 16578980 — intervention group
Group type: EXPERIMENTAL
Intervention: permethrin
Number of subjects: 10
Study 16578980 — intervention group
Group type: EXPERIMENTAL
Intervention: stress (combat videotape plus mental arithmetic)
Number of subjects: 10
Study 16578980 — intervention group
Group type: EXPERIMENTAL
Intervention: blinding
Number of subjects: 10
Study 12770957 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Small Incision Cataract Surgery (MSICS)
Number of subjects: 741
Study 12770957 — intervention group
Group type: COMPARATOR
Intervention: Extracapsular Cataract Surgery (ECCE)
Number of subjects: 741
Study 10685792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (2.5 to 4 mg/kg/day) plus MTX
Number of subjects: 40
Study 10685792 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 40
Study 10685792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 40
Study 9058181 — intervention group
Group type: EXPERIMENTAL
Intervention: music imaging
Number of subjects: 78
Study 9058181 — intervention group
Group type: COMPARATOR
Intervention: silent imaging
Number of subjects: 78
Study 9058181 — intervention group
Group type: COMPARATOR
Intervention: music listening
Number of subjects: 78
Study 9058181 — intervention group
Group type: COMPARATOR
Intervention: control conditions
Number of subjects: 78
Study 8088933 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparan sulfate pharmacodynamics identification programme using a personal computer
Number of subjects: 0
Study 3537785 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group A)
Number of subjects: 74
Study 3537785 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ketoconazole, 400 mg daily for five days beginning with the onset of menses for six menstrual cycles (Group B)
Number of subjects: 74
Study 3537785 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketoconazole, 100 mg daily for six months (Group C)
Number of subjects: 74
Study 3537785 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ketoconazole (Group B)
Number of subjects: 74
Study 3537785 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketoconazole (Group C)
Number of subjects: 74
Study 30620641 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Hybrid Closed Loop (e-HCL)
Number of subjects: 11
Study 30620641 — intervention group
Group type: COMPARATOR
Intervention: Standard Hybrid Closed Loop (s-HCL)
Number of subjects: 11
Study 29530423 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based educational intervention involving screening and structured discussion of a 52-min movie, and the SARAR approach via the PHAST model.
Number of subjects: 58
Study 29530423 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based educational intervention
Number of subjects: 58
Study 27380603 — intervention group
Group type: EXPERIMENTAL
Intervention: Ditto Preparation and Distraction
Number of subjects: 98
Study 27380603 — intervention group
Group type: COMPARATOR
Intervention: Standard Distraction
Number of subjects: 98
Study 23572413 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg orally three times a day for 48 hours
Number of subjects: 199
Study 23572413 — intervention group
Group type: COMPARATOR
Intervention: Saline (hydration)
Number of subjects: 199
Study 22159966 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Mitomycin C
Number of subjects: 50
Study 22159966 — intervention group
Group type: COMPARATOR
Intervention: Saline-soaked pledget (control)
Number of subjects: 50
Study 20123205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoplasty
Number of subjects: 86
Study 20123205 — intervention group
Group type: COMPARATOR
Intervention: Conventional angioplasty
Number of subjects: 86
Study 17347975 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. L-propionyl carnitine treatment for two months
Number of subjects: 14
Study 12663237 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg/day
Number of subjects: 34
Study 12663237 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40-120 mg/day
Number of subjects: 34
Study 11010580 — intervention group
Group type: EXPERIMENTAL
Intervention: DOSA pathway with domiciliary post acute care
Number of subjects: 0
Study 11010580 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical pathways
Number of subjects: 0
Study 9295114 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining right hand grasping the screwdriver
Number of subjects: 0
Study 9295114 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining left hand grasping the screwdriver
Number of subjects: 0
Study 9295114 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-handers imagining left hand
Number of subjects: 0
Study 9295114 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-handers imagining right hand
Number of subjects: 0
Study 8290486 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren) alone
Number of subjects: 18
Study 8290486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine HCl (Zantac) alone
Number of subjects: 18
Study 8290486 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium and ranitidine HCl in combination (V/Z)
Number of subjects: 18
Study 8290486 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium alone
Number of subjects: 18
Study 8290486 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine HCl alone
Number of subjects: 18
Study 8290486 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (V/Z)
Number of subjects: 18
Study 8290486 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric residence time for Treatments V, Z, and V/Z
Number of subjects: 18
Study 3728581 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm of oral tryptophan (group T)
Number of subjects: 40
Study 3728581 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 gm of oral glucose (group G)
Number of subjects: 40
Study 3728581 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm of oral tryptophan and 100 gm of oral glucose (group T + G)
Number of subjects: 40
Study 3728581 — intervention group
Group type: COMPARATOR
Intervention: Fasting (group C)
Number of subjects: 40
Study 3728581 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40
Study 29391363 — intervention group
Group type: EXPERIMENTAL
Intervention: Interorganisational educational intervention 'The Meeting Point'
Number of subjects: 0
Study 29391363 — intervention group
Group type: COMPARATOR
Intervention: Control group (hospital and nursing home)
Number of subjects: 0
Study 26957102 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Epidural Analgesia (CEA)
Number of subjects: 80
Study 26957102 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Patient Controlled Analgesia (IV-PCA)
Number of subjects: 80
Study 24399553 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg, 2 per day) with cognitive behavioral therapy
Number of subjects: 247
Study 24399553 — intervention group
Group type: COMPARATOR
Intervention: Placebo with cognitive behavioral therapy
Number of subjects: 247
Study 23250157 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total (fluoride abrasive dentifrice)
Number of subjects: 40
Study 23250157 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural White (whitening dentifrice)
Number of subjects: 40
Study 23250157 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence (10% carbamide peroxide) brushed with Colgate Total
Number of subjects: 40
Study 23250157 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence (10% carbamide peroxide) brushed with Natural White
Number of subjects: 40
Study 23250157 — intervention group
Group type: COMPARATOR
Intervention: Water (Control group)
Number of subjects: 40
Study 20020208 — intervention group
Group type: EXPERIMENTAL
Intervention: Family functioning
Number of subjects: 409
Study 20020208 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 409
Study 20020208 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure
Number of subjects: 409
Study 20020208 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV adherence
Number of subjects: 409
Study 18436195 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 1 g orally twice daily (b.i.d.)
Number of subjects: 140
Study 16148700 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure tonsillectomy (LT)
Number of subjects: 200
Study 16148700 — intervention group
Group type: COMPARATOR
Intervention: Cold knife tonsillectomy (CKT)
Number of subjects: 200
Study 12687827 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD+ pacing
Number of subjects: 75
Study 12687827 — intervention group
Group type: COMPARATOR
Intervention: DDD pacing
Number of subjects: 75
Study 11297005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (FG)
Number of subjects: 17
Study 11297005 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (GG)
Number of subjects: 17